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Introduction: The present study examines the levels of recently reported biomarkers, adenosine deaminase acting on
RNA (ADAR), C-C motif chemokine ligand 2 (CCL2), C-X-C motif chemokine 10 (CXCL10), signal transducers and activators
of transcription 1 (STAT1), and miR-146a in systemic lupus erythematosus (SLE) patients over multiple visits.
Methods: Peripheral blood leukocytes were collected from 65 healthy donors and 103 SLE patients, 60 of whom had
samples from 2 or more visits. Total RNA was isolated and analyzed for the expression of mRNA and microRNA using Taqman
real time PCR assays. Relative expression of I-IFN signature genes, chemokines, and miR-146a were determined by the ΔΔCT
method. Results were correlated with clinical data and analyzed by Wilcoxon/Kruskal-Wallis test and Fisher’s exact test.
Results: Levels of ADAR, CCL2, CXCL10, and STAT1 in SLE were significantly elevated compared with the healthy controls
(P <0.0001). ADAR, CCL2, and CXCL10 showed significant correlation with IFN score in both healthy donors (P <0.0033)
and SLE patients (P <0.0001). In SLE patients, miR-146a level was not significantly different from healthy controls nor
correlated to the IFN score. Two STAT1 populations were identified: a low STAT1 and a high STAT1 group. High STAT1
patient visits displayed higher (P ≤0.0020) levels of CCL2 and CXCL10 than the low STAT1 patient visits. STAT1 levels
correlated with IFN score in low STAT1 group but not in high STAT1 group. More importantly, high STAT1 levels appeared
as an enhancer of CCL2 and CXCL10 as indicated by the significantly stronger correlation of CCL2 and CXCL10 with IFN
score in high STAT1 patient visits relative to low STAT1 patient visits.
Conclusion: Our data indicate a novel role for STAT1 in the pathogenesis of SLE as an expression enhancer of CCL2 and
CXCL10 in SLE patients with high levels of STAT1. Future study is needed to examine the exact role of STAT1 in the
etiology of SLE.Introduction
Systemic lupus erythematosus (SLE) is a chronic systemic
autoimmune disease characterized by periods of increased
disease activity, referred to as flare-ups, and periods of re-
mission. Several genetic and environmental factors have
been implicated in SLE etiopathogenesis, but in recent* Correspondence: echan@ufl.edu
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distribution, and reproduction in any mediumyears increased type I interferon (IFN-I, IFNα and IFNβ)
expression has been discovered to play a key role in the ma-
jority of SLE patients, despite being known for over 30 years
that it is elevated in SLE patients [1-4]. Because of the tech-
nical challenges in measuring the numerous isoforms of
IFNα, one common way to evaluate IFN-I expression is to
examine the levels of common IFN-inducible genes, such
as 2′,5′-oligoadenylate synthetase (OAS1), myxovirus re-
sistance 1 (MX1), and lymphocyte antigen 6 complex locus
E (LY6E); the mRNA levels of these IFN-I-inducible genesioMed Central Ltd. This is an open access article distributed under the terms of
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interferon inducible gene that plays an important antiviral
and immunomodulatory function is the adenosine deami-
nase acting on RNA (ADAR). ADAR is an enzyme that cat-
alyzes the conversion from adenosine (A) to inosine (I) in
double-stranded RNA (dsRNA) substrate [8,9], with an im-
pact on RNA at different levels, such as mRNA splicing
and degradation [10,11]. Furthermore, ADAR1 has been
observed to suppress interferon regulatory factor (IRF)3
and protein kinase RNA-activated (PKR) and therefore
blocking IFN induction [12-14]. The ability of ADAR1 to
respond and regulate IFN-I production makes it an intri-
guing IFN-I-inducible gene to examine in SLE. Up to now,
ADAR1 expression has only been observed in T-cells of
SLE patients, as shown in a limited number of studies
[15-17]. In fact, Laxminarayana et al. showed that ADAR1
is upregulated approximately 3-fold in SLE patients [15].
The same group later observed the increased editing
of ADAR2 by ADAR1 in T-cells of SLE patients [16]. Add-
itionally, due to increased ADAR1 in SLE patients,
Orlowski et al. observed an increase of phosphodiesterase
8A1, which participates in the termination of cyclic nucleo-
tide signaling by hydrolyzing cAMP and cGMP and is acti-
vated by IFN and enhances T-cell adhesion [17].
Other IFN-I-inducible genes include signal transducers
and activators of transcription (STAT)1 and 2. STAT1 is
involved in type I, II, and III IFN signaling and has been
observed to be elevated in SLE [18]. In response to type
I IFN, STAT1 causes IFN receptor (IFNAR)1 and 2
dimerization, activation and phosphorylation of IFNAR
by Tyk2 and Jak1, and thus docking and phosphorylation
of STAT1 and STAT2 [19]. The heterodimer STAT1-
STAT2 is then translocated into the nucleus where it
can bind specific promoters playing a key role in IFN
signaling and production [20].
Besides STAT1 and ADAR, IFN-regulated chemokines
have become another important topic of research in recent
years [21]. Two of these chemokines have been shown to
be SLE biomarkers, and they are called C-C motif chemo-
kine ligand 2 (CCL2) and C-X-C motif chemokine 10
(CXCL10) [22]. CCL2, formerly referred to as monocyte
chemotactic protein-1 (MCP-1), is a potent recruiter of
monocytes, T-cells, basophils, and dendritic cells to the site
of infection or tissue damage, but it has no effect on neu-
trophils or eosinophils unless the N-terminus of CCL2 is
cleaved [18,23]. Some cell types such as monocytes, macro-
phages, and dendritic cells can primarily secrete CCL2,
which signals via the cell surface receptors CCR2 and
CCR4 and is upregulated by IFNα and IFNβ [24,25]. The
role of CCL2 is beneficial in clearing pathogens, but it has
also been involved in some pathological processes. In a
glomerulonephritis mouse model, CCL2 plays a role in
crescent formation and interstitial fibrosis supported by the
observation that anti-CCL2 antibodies can reduce crescentformation, renal impairment, and scarring, as well as T cell
and macrophage infiltration [26]. CCL2 has been observed
in the recruitment of T cells and monocytes/macrophages
in lupus nephritis and blockade of CCL2 ameliorates lupus
nephritis in MRL-(Fas)lpr mice [23,27]. In a serologic
proteome study by antibody microarray in SLE, CCL2 was
identified as one of the twelve upregulated proteins; fur-
thermore CCL2 was one of three chemokines that would
precede lupus flare, indicating that they are good predictors
of increased SLE activity [21].
CXCL10, also known as IFN gamma-induced protein
10 (IP-10), is a chemokine of the C-X-C motif family.
Similar to CCL2, CXCL10 is a potent attractor of mono-
cytes, macrophages, T-cells, natural killer (NK) cells, and
dendritic cells to sites of tissue damage and infection
[28,29]. CXCL10 is an IFN-response cytokine that binds
its CCL3 receptor and acts via Jak/STAT pathway activa-
tion [30-32]. Even though CXCL10 is a potent immune
responder for bacterial and viral infections and a critical
biomarker for organ transplant rejection, its role in the
pathogenesis of autoimmune diseases is not clear [33,34].
Furthermore, the combination of CXCL10 and CCL2
protein levels could be useful as prediction factor for up-
coming flares [22].
The reason behind upregulation and control of IFN in
SLE is not known, but some studies have recently
focused on the possible role played by selected micro-
RNAs (miRNAs). MiRNAs are small non-encoding 20-
to 23-nucleotide-long RNAs, that regulate their target
mRNA by binding to the 3′ UTR, causing translational
repression and/or degradation of targets. miR-146a is
one of the most significant miRNAs in regulating innate
immune response and tolerance [35] and it was first
shown to be involved in toll-like receptor (TLR) regulation
through the nuclear factor (NF)-кB pathway [36]. miR-
146a would function to attenuate the immune response
and regulate inflammation in normal immune response
and autoimmune disorders, and it is also a critical regula-
tor of endotoxin-induced tolerance and cross-tolerance
[37-39]. To date, miR-146a has been found in association
with autoimmune diseases such as Sjögren’s syndrome
[40], psoriasis [41,42], and rheumatoid arthritis [43-45].
Tang et al. reported that miR-146a was under-expressed
in peripheral blood mononuclear cells (PBMCs) of Chinese
SLE patients [46]. miR-146a was significantly lower in pa-
tients with active SLE with proteinuria compared to those
with inactive SLE [46]. Additionally, SLE patients displayed
an inverse correlation between miR-146a expression and
IFN score [46]. Tang et al. also demonstrated that reduction
of miR-146a may enhance the signaling due to elevated
levels of STAT1 and IRF5 which leads to increased produc-
tion of IFN [46]. The reduced levels of miR-146a observed
in Chinese SLE patients could potentially explain elevation
of IFN by loss of regulation of STAT1 expression.
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STAT1, ADAR, CCL2, CXCL10, and miR-146a in SLE
patients and healthy controls, demonstrating that all ex-
cept for miR-146a correlate with IFN score in both SLE
patients and healthy donors.
Methods
Healthy donors’ and SLE patients’ demographic data
Whole blood was collected from a total of 103 SLE pa-
tients and 65 healthy controls enrolled in the University
of Florida Center for Autoimmune Diseases registry
from 2008 to 2011. Healthy donors (HD) were selected
based on no history of autoimmune disease, and all SLE
patients satisfied the American College of Rheumatol-
ogy (ACR) criteria [47]. Healthy donors only visited the
clinic once, therefore, they represent a single visit.
There were a total of 180 SLE visits with sequential
samples collected in 60 SLE patients (Table 1). SLE pa-
tients and healthy controls were segregated by ethnic
profile (Table 1). All human blood samples were ob-
tained from enrolled individuals with the approval of
the institutional review board (IRB) at the University of
Florida. This study meets and is in compliance with all
ethical standards in medicine and informed consent wasTable 1 Demographic data of SLE patients and
healthy donors
SLE HD
Number of cases 103 65
Number of visits (2 or more) 180 (60) 65 (0)
Mean age, years (range) 44 (25–68) 33 (19–59)
Sex, female/male/unknown, n 90/13/0 31/9/24
Race, AA/EA/LA/AsA/IrA/unknown1, n 35/50/12/3/3/0 10/18/6/3/2/25
Race by visit
(AA/EA/LA/AsA/IrA/unknown)1, n
64/86/20/7/3/0 10/18/6/3/2/25
Active/inactive by SLEDAI,
number of patients
49/131 N/A
Main clinical features,
number of patients
Malar rash 9/94 N/A
Discoid lesions 2/101 N/A
Photosensitivity 8/95 N/A
Oral ulcers 7/96 N/A
Arthritis 17/86 N/A
Serositis 4/99 N/A
Pleuritis 5/98 N/A
Nephritis 49/54 N/A
Seizures 2/101 N/A
Psychosis 1/102 N/A
1AA, African Americans; AsA, Asian Americans; EA, European Americans; HD,
healthy donors with no history of autoimmune disease; IrA, interracial
Americans; LA, Latino Americans; unknown, undisclosed race; N/A,
not applicable.obtained from all patients according to the Declaration
of Helsinki.
Leukocytes and RNA purification
Peripheral blood leukocytes were collected from whole
blood using Ambion LeukoLOCK kit (Ambion, Austin, TX,
USA). LeukoLOCK filters were washed twice with 3 ml of
PBS and stabilized with 3 ml of RNAlater solution. Stabi-
lized filters were stored for a minimum of 24 h at −80°C be-
fore collecting total RNA. Total RNA, including small
RNAs, was collected using the “Alternative Protocol” (ver-
sion 0602, Ambion) for the extraction of RNA from cells
captured on LeukoLOCK filters using TRI reagent.mRNA and microRNA quantitative RT-PCR
OAS1 (Hs00973637_m1), MX1 (Hs00895608_m1), LY6E
(Hs00158942_m1), STAT1 (Hs01013996_m1), CCL2
(Hs00234140_m1), CXCL10 (Hs00171042_m1), ADAR
(Hs00241666_m1), TNFα (Hs00174128_m1), and pri-
miR-146a (Hs033303259_pri) levels were analyzed by
TaqMan mRNA assay primers (Applied Biosystems,
Foster City, CA, USA). mRNA qRT-PCR was performed
as a duplex with 18S rRNA assayed as the normalizer.
mRNA was transcribed to cDNA using the TaqMan High-
Capacity cDNA Reverse Transcription Kit followed by
quantitative (q)PCR using TaqMan Fast Advance PCR
Master Mix (Applied Biosystems). miR-146a (000468;
Catalogue # 4427975) was analyzed by miRNA qRT-PCR
using the TaqMan MicroRNA Reverse Transcription Kit,
TaqMan Fast Advance PCR Master Mix, and TaqMan
MicroRNA primers (Applied Biosystems). All reactions
were analyzed using StepOne Real-Time PCR System
(Applied Biosystems).Anti-dsDNA ELISA
After the collection of leukocytes with the LeukoLOCK fil-
ters, the leukocyte free blood was transferred to 10 ml
Vacutainer SST plus blood-collection tubes (BD, Franklin
Lakes, NJ, USA). Blood was centrifuged at 1,000 g for
20 minutes. The plasma was transferred to a 15-ml conical
tube and stored at −20°C. Anti-dsDNA ELISA was per-
formed as previously described [48]. In brief, anti-human
IgG secondary antibody was used and samples were con-
sidered positive when the absorbance was greater than the
mean plus three SD from the healthy controls.Complement levels
C3 and C4 complement levels were obtained from clin-
ical data. C3 levels lower than 90 mg/dl and C4 levels
less than 15 mg/dl were considered as low complement
levels in the analysis.
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The expression of three known type-I IFN signature genes,
MX1, OAS1, and LY6E, was z-transformed into IFN score
as previously shown [1,49]. The SLE disease activity index
(SLEDAI) was used to classify the patients into active
(SLEDAI >4) or inactive (SLEDAI ≤4) at the time of the
visit (Table 1) [50,51].
Cell culture and innate immune ligand stimulation
Human THP-1 cells were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA).
THP-1 cells were maintained in RPMI containing 10% (v/v)
FBS (Mediatech, Manassas, VA, USA) and 100 U/ml peni-
cillin-streptomycin (Mediatech). For analysis of THP-1
monocyte response to ligand in vitro, log-phase cells were
seeded at 5 × 105 cells/ml in a 24-well plate. Cells were
stimulated with the following agonists: 1,000 ng/ml of lipo-
polysaccharide from S. enterica serotype Minnesota Re595
(LPS Se, TLR4 ligand, Ultrapure grade, Sigma-Aldrich
Corp. St. Louis, MO USA), 0.10 and 1.0 ng/ml IFNα2 (PBL
Interferon Source, Piscataway, NJ, USA), and 0.10 or
1.0 ng/ml IFNβ (PBL Interferon Source). TLR4 ligands
were reconstituted in endotoxin-free water and used at
concentrations as reported before [38]. IFNα2 and IFNβ
were reconstituted in endotoxin-free PBS with 1 mg/ml
BSA to make 5-μg/ml stocks stored at −80°C.
Data analysis
The copy number of miR-146a was normalized to total
loaded RNA, whereas mRNA levels were normalized to
18S RNA. The copy number of miR-146a was determined
using a standard curve with synthetic miR-146a (Integrated
DNA Technologies Inc., Coralville, IA, USA) [52]. Relative
expression of mRNA compared to controls was determined
by the ΔΔCT (cycle threshold) method [53]. Analyses were
performed using SAS version 9.2 and JMP Genomics
version 5 (SAS, Cary, NC, USA). The Wilcoxon/Kruskal-
Wallis test was used to evaluate significance between
groups, whereas the Wilcoxon signed rank test for matched
pairs was used to evaluate SLE patients with two visits.
P-values <0.05 were considered significant. Before applying
ordinary linear regression analyses, the distributions of
datasets were confirmed for normality. The coefficient of
determination (r2) was used to determine linear correlation.
Significant differences between slopes was evaluated by
analysis of covariance (ANCOVA). The Generalized
Estimating Equation (GEE) model for Repeated Measures
was used to account for possible with-in subject effects
from patients with multiple visits [54].
Results
Expression of candidate biomarkers in the SLE cohort
To determine whether previously reported biomarkers
were elevated in our SLE patient cohort, we measuredthe biomarker expression levels in HD, active SLE, and
inactive SLE patient visits (Figure 1). The SLE cohort
was segregated by SLEDAI into active SLE (49 visits,
SLEDAI >4) and inactive SLE (131 visits, SLEDAI ≤4).
The level of IFN-I was estimated by quantifying the ex-
pression of IFN-inducible genes. The IFN score, STAT1,
ADAR, CCL2, and CXCL10 levels were significantly ele-
vated at both active and inactive SLE patient visits com-
pared to HD (Figure 1A-E), establishing and confirming
that these biomarkers were aberrantly overexpressed in our
SLE patients. To explore if these biomarkers were capable
of distinguishing disease activity status, active and inactive
patient visits were compared to one another. No significant
difference was observed between active and inactive SLE
patient visits for IFN score (Figure 1A, mean ± SD, 62.7 ±
6.1 units versus 57.8 ± 4.9 units), ADAR (Figure 1C, 5.27 ±
0.31 fold versus 5.27 ± 0.23 fold), and CXCL10 (Figure 1E,
158.1-fold ± 26.6 versus 120.0-fold ± 10.5), but STAT1
(Figure 1B, 44.8 ± 10.7 vs 34.4 ± 6.6 fold, P = 0.033) and
CCL2 (Figure 1D, 18.2-fold ± 3.1 versus 9.96-fold ± 1.42,
P = 0.0061) were significantly elevated in active SLE com-
pared to inactive SLE patient visits. TNFα, which is not
generally involved in the pathogenesis of SLE, was used as
a negative control. As expected, TNFα was not significantly
different among the three groups (Figure 1F). Similarly
miR-146a did not display any significant difference among
active SLE, inactive SLE, and HD (Figure 1G). To validate
this, we determined the levels of the primary transcript of
miR-146a (pri-mir-146a) which also did not demonstrate
any significant difference among active SLE, inactive SLE,
and HD. With the exception of miR-146a, these results are
consistent with reports on SLE patients with elevated IFN
score compared to HD [1,49] as well as upregulated levels
of IFN signature genes (STAT1 and ADAR) [15-17] and
chemokines (CCL2 and CXCL10) [21].
The clinical and expression data were correlated with
anti-dsDNA autoantibody level, which is an indicator for
patients’ disease activity in certain patients [55-58]. De-
creases in C3 and C4 levels correlated with SLE activity and
renal damage as well as increased levels of anti-dsDNA
antibodies [59]. Anti-dsDNA autoantibody levels have also
been used for sub-classification of SLE patients [60,61]. SLE
patient visits and HD were segregated into anti-dsDNA(+)
and anti-dsDNA(−). Patient visits that were anti-dsDNA(+)
displayed higher SLEDAI and decreased C3 and C4 levels
(Figure 2A-C). The results for the remaining biomarkers
(Figure 2D-K) closely resembled those from active versus
inactive SLEDAI results (Figure 1).
The influence of race in anti-dsDNA, IFN score, STAT1,
CCL2, and CXCL10 were also examined. African Americans
(AA) and European Americans (EA) contributed to 83.3%
of the visits, followed by Latin Americans (LA) and Asian
Americans (AsA) for 15%, and interracial Americans (IrA)
for less than 2% of patient visits (Table 1). Due to the small
Figure 1 Correlation of IFN score, STAT1, ADAR, CCL2, CXCL10, and miR-146a levels to systemic lupus erythematosus (SLE) disease
activity. (A) IFN score, (B) STAT1, (C) ADAR, (D) CCL2, and (E) CXCL10 were significantly elevated in SLE patient visits (active and inactive disease
activity are indicated as + and - respectively) compared to healthy donors (HD). No statistical difference was detected between active and inactive
SLE for IFN score, ADAR, or CXCL10. (F-H) TNFα, pri-miR-146a, and miR-146a did not show any significant difference among the groups. STAT,
signal transducers and activators of transcription; ADAR, adenosine deaminase acting on RNA; CCL2, C-C motif chemokine ligand 2; CXCL10,
C-X-C motif chemokine 10.
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In general, results show that higher levels of anti-dsDNA,
IFN score, STAT1, CCL2, and CXCL10 were observed in all
race groups analyzed (Additional file 1: Figure S1). The lack
of statistically significant differences between SLE and HD
in certain groups, such as LA, might be due to the smaller
sample sizes.Figure 2 Correlation of IFN score, STAT1, ADAR, CCL2, CXCL10, and m
autoantibodies. (A) Systemic lupus erythematosus disease activity (SLEDA
patient visits. (B, C) C3 and C4 were significantly lower in anti-dsDNA(+) th
CCL2, and (H) CXCL10 were significantly elevated in SLE patient visits com
detected between anti-dsDNA(+) and anti-dsDNA(−) patients for IFN score
show any significant difference among the groups. STAT, signal transducer
RNA; CCL2, C-C motif chemokine ligand 2; CXCL10, C-X-C motif chemokineBy comparing patients of different race (Additional file 1:
Figure S2), the levels of the parameters examined were all
higher in AA than EA, LA, and AsA. In particular, AA had
significantly higher SLEDAI (P = 0.024), anti-dsDNA level
(P = 0.044), IFN score (P = 0.0005), STAT1 (P = 0.0011),
CCL2 (P = 0.0004), and CXCL10 (P = 0.0004) than EA. Fur-
thermore, AA had significantly (P ≤0.014) higher IFN score,iR-146a levels to anti-double-strandard DNA (dsDNA)
I) scores were significantly higher in anti-dsDNA(+) than anti-dsDNA(−)
an in anti-dsDNA(−) patients. (D) IFN score, (E) STAT1, (F) ADAR, (G)
pared to healthy donors (HD), but no statistical differences were
, ADAR, or CXCL10. (I-K) TNFα, pri-miR-146a, and miR-146a did not
s and activators of transcription; ADAR, adenosine deaminase acting on
10.
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Figure S2B-F). Also in this case, the lack of additional sta-
tistically significant results for LA and AsA might be due
to the small sample sizes. However, AA clearly displayed
increased biomarker levels more than any other race.
Biomarker interrelationship in SLE patients with
return visits
To expand upon the interrelationship of these biomarkers,
data from SLE patients with two consecutive visits were
segregated for analyses by increasing or decreasing IFN
score by at least 50% from the first to the second visit. Pa-
tients with increasing IFN score from one visit to the next
(n =13; P = 0.0001, Figure 3A) displayed a significant in-
crease in STAT1 (P = 0.0017), CCL2 (P = 0.0086), CXCL10
(P = 0.038), and miR-146a (P = 0.0034). Similarly, for SLE
patients with increasing STAT1 by at least 50% between
the first and second visit (n = 25; P <0.0001, Figure 3B),
significant increases were observed for IFN score (P =
0.027), CCL2 (P <0.0001), CXCL10 (P = 0.0003), and miR-
146a (P = 0.0078). The strong correlation between STAT1,
CCL2, and CXCL10 were expected; however, correlation
between IFN score and increasing STAT1 was weaker
than expected. This may be indicating that high STAT1
levels do not necessarily translate into high levels of IFN-I.
The highly significant correlation between miR-146a levels
and IFN score in the return visits was unexpected, as theFigure 3 Systemic lupus erythematosus (SLE) patients with two visits
from the first and second visits for each patient is denoted by an individua
first to the second visit showed significant increase in STAT1, CCL2, CXCL10
significant increase in IFN score, CCL2, CXCL10, and miR-146a. (C) SLE patie
showed significant decrease only in STAT1 and CXCL10. (D) Patients ranked
CXCL10. STAT, signal transducers and activators of transcription; CCL2, C-Clevel of miR-146a in SLE was not significantly different
from HD (Figures 1H and 2H) and also it was previously
reported to be decreased in SLE and inversely correlated
with IFN score in a Chinese SLE cohort [46].
SLE patients who had decreasing IFN score by at least
50% between first and second visit (N = 32; P <0.0001,
Figure 3C) displayed a significant decrease in STAT1 (P =
0.0002) and CXCL10 (P = 0.0002), but not in CCL2 and
miR-146a. Similarly, SLE patients with decreasing STAT1
(n = 13; P = 0.0001, Figure 3D) had significant decrease in
IFN score (P = 0.0001) and CXCL10 (P = 0.0004), whereas
no significant changes in CCL2 and miR-146a were ob-
served. By ranking patients according to decreasing IFN
score or STAT1, the reversal of the results from ranking
by increasing IFN score or STAT1 should ideally have
been observed. Interestingly, the exception was observed
only for CCL2 and miR-146a (Figure 3C, D).
Relationship of IFN score to other biomarkers
To better understand whether the association of IFN
score with the other biomarkers in paired patient-visits
could be expanded, levels of ADAR, CCL2, and CXCL10
from the entire cohort of SLE patient visits and HD were
correlated to IFN score (Figure 4). ADAR, CCL2, and
CXCL10 displayed significant coefficient of determin-
ation (r2) in both SLE and HD (Figure 4). The consistent
significant correlations of these genes to IFN from theranked by increasing or decreasing IFN score and STAT1. Data
l color line. (A) SLE patients ranked by increasing IFN score from the
, and miR-146a. (B) Patients ranked by increasing STAT1 also showed
nts ranked by decreasing IFN score from the first to the second visit
by decreasing STAT1 showed significant decrease in IFN score and
motif chemokine ligand 2; CXCL10, C-X-C motif chemokine 10.
Figure 4 ADAR, CCL2, and CXCL10 levels correlate with IFN score in both systemic lupus erythematosus (SLE) patients and healthy
donors (HD). (A) ADAR, (B) CCL2, and (C) CXCL10 display direct and significant r2 with IFN score for both SLE visits and HD. ADAR, adenosine
deaminase acting on RNA; CCL2, C-C motif chemokine ligand 2; CXCL10, C-X-C motif chemokine 10.
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rantly high pathogenic levels of IFN in SLE patient visits
(Figure 4, left panels) was indicative of a normal intrinsic
response of ADAR, CCL2, and CXCL10 to IFN produc-
tion. Contrary to an earlier report showing that the level
of miR-146a was negatively correlated with IFN score [46],
miR-146a as well as pri-miR-146a did not display any sig-
nificant correlation with IFN score in either HD or SLE
patients (data not shown). Surprisingly, in the same type
of analysis, STAT1 did not display a significant correlation
to IFN score either (data not shown). Further analysis of
STAT1 expression revealed two populations after applying
a log10 transformation (Log[STAT1]) in both HD and SLE
patients (Figure 5A). Using an arbitrary cut off of 1.50 Log
[STAT1] to segregate STAT1 results, values below 1.50
were referred as the low-STAT1 group and above 1.50
were the high-STAT1 group (Figure 5B, C). In the low
STAT1 group, SLE patient visits displayed significantly
higher expression of STAT1 compared to HD (2.44-fold,
P <0.0001, Figure 5B), but in the high-STAT1 group, no
significant difference was observed (Figure 5C). Further-
more, the low-STAT1 group displayed significant positive
association between STAT1 and IFN score in both HD
(Figure 5D) and SLE patients (Figure 5E). In contrast, in
the high-STAT1 group there was no correlation between
STAT1 and IFN score (data not shown).STAT1 levels correlate with SLE activity
The effects of high and low STAT1 on IFN score and
ADAR appeared to be related to the active versus inactive
status of SLE (SLEDAI, Figure 1A, C) and anti-dsDNA(+)
versus (−) patients (Figure 2A, C) where IFN score and
ADAR were significantly higher than in HD, but not sig-
nificantly different between SLE patient visits with high
and low STAT1 (Figure 6A, B). CCL2 was significantly dif-
ferent between active and inactive SLE, and between HD
and active and inactive SLE as well (Figure 1D), which re-
sembles the results of anti-dsDNA (+ versus -) (Figure 2D)
and high- versus low-STAT1 comparisons (Figure 6D).
Similar observations are valid for CCL2, with the addition
that there is a difference in CCL2 expression between
high- and low-STAT1 SLE (Figure 6C). As both SLEDAI
active and anti-dsDNA (+) are indicators of increased dis-
ease activity, these results indicate that patients with high
STAT1 are also in a more active disease state than those
with low STAT1.
To determine whether ethnicity could be a confound-
ing factor for the effects of high and low STAT1, IFN
score, CCL2, and CXCL10 levels were segregated based
on ethnicity and high and low STAT1 (Additional file 1:
Figure S3A-C). Overall, high STAT1 patient visits did
not show a significant difference among AA, EA, and LA.
However, low-STAT1 AA patients showed significantly
Figure 5 Bimodal distribution of STAT1 into high and low groups. (A) The log10 transformation of STAT1 shows a bimodal distribution of
STAT1 with two populations (high- and low-STAT1 groups) with a cut off at 1.5 log[relative fold-change] of STAT1 (Log[STAT1]) for both healthy
donor (HD) and SLE patient visits. (B) The low-STAT1 groups displayed significant difference of STAT1 in SLE patient visits compared to HD. (C)
On the other hand, the high-STAT1 groups showed no significant difference between SLE and HD. (D, E) In the low-STAT1 group, STAT1 levels
display a direct correlation to the IFN score in SLE patient visits and HD. STAT, signal transducers and activators of transcription.
Dominguez-Gutierrez et al. Arthritis Research & Therapy 2014, 16:R20 Page 8 of 14
http://arthritis-research.com/content/16/1/R20higher IFN score, CCL2 and CXCL10 compared to other
groups (Additional file 1: Figure S3). These results indi-
cated that high- and low-STAT1 groups were identified
essentially in all ethnicities, and differences in IFN
score, CCL2, and CXCL2 levels were observed among
low-STAT1 groups but not among the high-STAT1
groups.Figure 6 High levels of CCL2, CXCL10, and miR-146a compared to low
patients. (A) IFN score, (B) ADAR, (C) CCL2, (D) CXCL10, (E) pri-miR-146a, a
donors (HD), which were segregated by high and low STAT1 levels demon
CCL2, CXCL10, and miR-146a than those with low STAT1. STAT, signal trans
acting on RNA; CCL2, C-C motif chemokine ligand 2; CXCL10, C-X-C motif cSTAT1 influences the covariance of IFN score with ADAR,
CCL2, and CXCL10
To determine whether high versus low STAT1 levels af-
fected the correlation between IFN score and the other
biomarkers, we analyzed these parameters in patients with
high versus low STAT1 expression (Figure 7). Even though
ADAR expression was reported to be STAT1-independentSTAT1 in high STAT1 systemic lupus erythematosus (SLE)
nd (F) miR-146a were compared in SLE patient visits and healthy
strating that patients with high STAT1 SLE expressed higher levels of
ducers and activators of transcription; ADAR, adenosine deaminase
hemokine 10.
Figure 7 Effect of high versus low STAT1 expression in ADAR, CCL2, and CXCL10 correlation with IFN score. (A) ADAR, (B) CCL2, and (C)
CXCL10 displayed a significant linear coefficient of determination (r2) with IFN score for high STAT1 (HS, blue, left panels). For the SLE patient
visits with low STAT1 (LS, red, left panels) r2 resembled that of the LS healthy donors (HD) (black, right panels). (B, C) The slopes of high STAT1 for
CCL2 and CXCL10 were significantly higher than those for patient visits with low STAT1 (left panels). ADAR, adenosine deaminase acting on RNA;
CCL2, C-C motif chemokine ligand 2; CXCL10, C-X-C motif chemokine 10.
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P <0.0001), high-STAT1 SLE (blue, r2 = 0.35, P = 0.0002)
patients, and low-STAT1 HD (black, r2 = 0.24, P <0.0001)
displayed significant association between ADAR and IFN
score (Figure 7A). Similarly, CCL2 was significantly associ-
ated with IFN score in patient visits with low STAT1 SLE
(r2 = 0.07, P <0.0010), patient visits with high-STAT1 SLE
(r2 = 0.76, P <0.0001), and HD with low STAT1 (r2 = 0.08,
P = 0.0002); also CXCL10 displayed significant association
with IFN score for SLE patients with low STAT1 (r2 = 0.09,
P = 0.0003), patient visits with high STAT1 SLE (r2 = 0.30,
P = 0.0008), and HD with low STAT1 (r2 = 0.08, P = 0.027,
Figure 7B, C).
The slope of the linear regression represents the rate
of change of ADAR, CCL2, and CXCL10 per unit of
change in IFN score. This led to the intriguing possibility
that patient visits with high STAT1 have a higher slope
than those with low STAT1. ANCOVA was used to test
if the slopes were significantly different (Figure 7).
ADAR/IFN scores were not significantly different be-
tween high- and low-STAT1 patients (Figure 7A, blue
versus red line, P-value not shown), but CCL2/IFN
score and CXCL10/IFN score slopes were significantly
higher in the high-STAT1 (HS) patients compared tothe low STAT1 (LS) patients (Figure 7B, C, blue versus
red line). This suggests that high STAT1 levels may en-
hance CCL2 and CXCL10 expression potentially in-
duced by IFN.
Next, we studied whether ethnic background could influ-
ence the association of IFN score with CCL2 and CXCL10
and altered the effects of high and low STAT1 (See
Additional file 1: Figure S4). Influence of ethnic background
appeared to be minimal on CCL2 in high-STAT1 patient
visits. CCL2 in high-STAT1 AA, EA, and LA displayed very
good linear correlation (r2 >0.59, P ≤0.0018) with IFN score
(See Additional file 1: Figure S4A, C, E). Low-STAT1 EA
and LA also showed good linear correlation (r2 ≥0.16,
P ≤0.039, red, Additional file 1: Figure S4C, E); however,
low-STAT1 AA did not display a linear correlation between
CCL2 and IFN score (See Additional file 1: Figure S4A).
CXCL10 had a significant correlation (r2 >0.24, P ≤0.032)
with IFN score for high-STAT1 AA and EA (See Additional
file 1: Figure S4B, D); however, CXCL10 had significant cor-
relation (r2 >0.25, P ≤0.0002) with IFN score for low-
STAT1 EA and LA (See Additional file 1: Figure S4A, D,
F). AsA could not ascertain significant correlations for
CCL2/IFN score and CXCL10, probably due to the small
sample size (data not shown).
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type I IFN
TLRs have been implicated to play a role in SLE pathogen-
esis. To model the response of STAT1, CCL2, and CXCL10
as well as IFN-I, TLR4 was stimulated in human monocytic
THP-1 for 24 h with 1,000 ng/ml of LPS. IFN score in-
creased at around 4 h and peaked around 8 h (Figure 8A).
In 1.0 ng/ml of IFNα2-treated and 0.1 ng/ml of IFNβ-
treated THP-1 cells, IFN score displayed a similar trend as
in LPS treatment (Figure 8F, K); however for 1.0 ng/mlFigure 8 THP-1 response to IFNα, IFNβ, and LPS over a period of 24 h
and lysates were harvested at various times from 2 to 24 h for RNA isolation a
CCL2 (C, H, M), CXCL10 (D, I, N), and miR-146a (E, J, O) were evaluated at 0.1
lipopolysaccharide; STAT, signal transducers and activators of transcription; CC
UTX, untreated.IFNβ-treated cells, IFN score increased up till 12 h
(Figure 8K), whereas 0.1 ng/ml-treated cells displayed little
change (Figure 8F). These results demonstrated THP-1 re-
sponsiveness to IFN-I as well as the fact that they were cap-
able of IFN-I production.
Interestingly, whereas LPS displayed a gradual, long-
term increase of CCL2 and CXCL10, IFNα2 and IFNβ
treatments displayed rapid increases followed by decreases
of CCL2 and CXCL10. After LPS stimulation, STAT1 did
not increase till 4 h and reached its peak expression at 8 h. THP-1 cells were treated with different doses of IFNα, IFNβ, and LPS
nd analyses. IFN score (A, F, K), and the expression of STAT1 (B, G, L),
and 1.0 ng/ml of IFNα2 and IFNβ as well as 1,000 ng/ml of LPS. LPS,
L2, C-C motif chemokine ligand 2; CXCL10, C-X-C motif chemokine 10;
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IFNα2 or IFNβ, STAT1 increased at 2 h, peaking at 8 h
(Figure 8G, L). CCL2 increased at 2 h in LPS-treated
THP-1 cells and continued to increase during the 24-h
period (Figure 8C); however this was not until after max-
imum expression of STAT1 was reached (Figure 8B), and
CCL2 began to rapidly increase (Figure 8C). CCL2 in-
creased at 2 h in 0.1 and 1.0 ng/ml IFNα2-treated as well
as 0.1 ng/ml IFNβ-treated THP-1 cells, but it peaked at
4 h and began to decrease rapidly (Figure 8H). For 1.0 ng/
ml IFNβ treatment of THP-1 cells, the peak was shifted by
2 h so that CCL2 peaked at 2 h and began to rapidly de-
crease (Figure 8M). CXCL10 displayed a trend similar to
CCL2 for 1.0 ng/ml IFNα2-treated and 0.1 ng/ml IFNβ-
treated THP-1 cells (Figure 8I, N). In 1.0 ng/ml IFNβ
treatment of THP-1 cells, CXCL10 continued till 8 h
(Figure 8N). These results indicated that CCL2 and
CXCL10 rapidly responded to IFNα2 and IFNβ stimula-
tion whereas TLR4 stimulation appeared to induce a slow
gradual increase, but then a rapid increase after STAT1
reached its maximum expression.
miR-146a appeared to differ in its response from the
other biomarkers. LPS upregulated miR-146 3-fold and
it rapidly reached a peak of an 11-fold increase at 12 h
(Figure 8E). miR-146a in IFNα2- or IFNβ-treated cells
showed a modest of 3- to 4-fold peak at 8 h, potentially
indicating that IFN-I did not induce significant produc-
tion of miR-146a (Figure 8J, O).
Discussion
In this study, expression of previously identified SLE bio-
markers was examined and correlation tested with demo-
graphic and clinical parameters, focusing on the analysis of
a possible correlation among them. The primary analyses
used ordinary linear regression, even for data from multiple
visits, as reported in Figures 4, 5, and 7. Alternatively, the
GEE model for repeated measures was also used to ac-
count for possible within-subject effects from patients with
multiple visits [54]. When we compared the parameters
(slope and significance) from the GEE and ordinary linear
regression, the results were practically identical (data not
shown). It is known that unless the vast majority of the
samples have repeated measures (patients with multiple
visits), the ordinary linear regression is expected to closely
approximate the GEE model [64]. Furthermore, even if
there was strong correlation between visits of patients, or-
dinary linear regression would underestimate the correl-
ation because it assumes that the visits are independent;
therefore, the correlations of ordinary linear regressions are
more stringent than those of GEE [64]. In addition, we also
assessed the normality of each dataset before applying lin-
ear regression. With the exception of STAT1, the IFN score,
ADAR, CCL2, and CXCL10 resembled normal distribu-
tions (data not shown). In most cases when dealing withsuch large datasets, even moderate deviations from nor-
malcy are not critical due to the central limit theorem [65].
For these reasons, we decided to report ordinary linear re-
gression rather than the more complex GEE model for re-
peated samples.
Biomarker assessment
Our results show that ADAR, STAT1, CCL2, and CXCL10
levels were significantly elevated in the SLE cohort as
expected. This is in part validated by previously published
results showing increased levels of these biomarkers and
their correlation to IFN-I production in SLE patients
[1,2,6,21,22,66]. Furthermore, our study shows that THP-1
cells treated with IFNα2 or IFNβ display up to 18-fold in-
crease of STAT1, 25-fold increase of CCL2, and 700-fold
increase of CXCL10, confirming that these genes respond
to IFN-I stimulation.
Tang et al. reported miR-146a under-expression in SLE
PBMCs [46], whereas we did not observe a decrease or a
difference between patients with active or inactive SLE for
miR-146a expression in peripheral blood leukocytes of SLE
patients in our cohort. Luo et al. [67] hypothesize that a
functional variant in the miR-146a promoter may be re-
sponsible for decreased levels of miR-146a in SLE, so the
pri-miR-146a levels should be decreased in our population;
however, no significant differences in pri-miR-146a expres-
sion were observed in our population. Furthermore, Tang
et al. reported inverse correlation between miR-146a and
IFN score in their SLE cohort, while we did not observe a
significant correlation in our cohort. A significant increase
in miR-146a was observed only in SLE patients with in-
creasing IFN score between the initial and the second visit
[36]. Other possible explanations for the discrepancy be-
tween the two datasets could be the difference in cell popu-
lations and racial composition in our cohort versus the one
examined by Tang et al. and Luo et al. [46,67]. As for the
THP-1 monocyte cell model, IFN-I weakly stimulated miR-
146a expression compared to LPS. All these results suggest
that the role of miR-146a in regulating IFN-I in our cohort
of SLE patients may have been limited.
Biomarker connections
Previous reports have demonstrated the involvement of
ADAR mRNA and CCL2 and CXCL10 protein in SLE
[15-17,22]. In published literature, ADAR mRNA and
CCL2, CXCL10 protein levels displayed a positive associ-
ation with IFN score [11,21,22,68]. Similarly in our cohort,
directly correlation between IFN score and mRNA levels of
ADAR, CCL2, and CXCL10 was observed. This was ob-
served not only in SLE but in HD as well, potentially indi-
cating that these genes are responding normally to IFN
even when at levels aberrantly elevated. Unlike reports from
previous studies, STAT1 did not correlate well with the
IFN score in the SLE patient population [69,70]. Instead,
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the expression was associated with IFN score. Patients
paired by two visits that were ranked by increasing IFN
score demonstrate strong covariance with STAT1, but the
covariance between IFN score and increasing STAT1 ap-
peared to be weaker. In paired SLE patient visits, decreasing
IFN scores or STAT1 level is accompanied by a decrease of
the other biomarkers suggesting that STAT1 and IFN-I
may be driving factors.
When SLE patient visits are grouped into high and low
STAT1, high-STAT1 SLE patient visits showed significantly
higher levels of CCL2 and CXCL10. After grouping by high
and low STAT1, the high-STAT1 patient visits showed a sig-
nificantly increased slope for CCL2/IFN and CXCL10/IFN
scores compared to low-STAT1 SLE patient visits. This en-
hanced response by CCL2 and CXCL10 to IFN-I in high-
STAT1 patients may be due in part to the role of STAT1 in
activation of CCL2 and CXCL10 [71-73]. Hence, STAT1
levels appear to be enhancing chemokine response to IFN-I.
Furthermore, THP-1 cells treated with IFNα2, IFNβ, or
even LPS, demonstrated that IFN score, STAT1, CCL2,
CXCL10 and miR-146a were upregulated in a time-
dependent manner. IFNα2 or IFNβ treatment of THP-1
cells shows that cells expressed decreased levels of CCL2
and CXCL10 shortly after reaching their peak expression,
whereas LPS treatment displayed a steady increase of
CCL2 and CXCL10 with a less rapid induction compared
to their expression after IFNα2 or IFNβ stimulation. After
STAT1 peak expression in LPS-treated THP-1 cells, CCL2
and CXCL10 expression rapidly accelerated. On the con-
trary, IFNα2 and IFNβ treatment of THP-1 cells shows
that CCL2 and CXCL10 both started decreasing after
reaching their peak expression, whereas STAT1 continued
to increase with IFNα2 or IFNβ stimulation. These results
indicate that CCL2 and CXCL10 respond differently to
TLR4 stimulation compared to IFN signaling. It also indi-
cates that CCL2 and CXCL10 response to IFN-I is rapid
but short compared to TLR signaling, as IFN score corre-
lates with greater increase of CCL2 and CXCL10 in the
high-STAT1 patients than in low-STAT1 patients. The re-
sults of TLR4 stimulation suggest that at least in the high-
STAT1 patient population CCL2 and CXCL10 are being
driven by TLR signaling rather than IFN-I directly since
IFN-I stimulation caused a rapid increase followed by an
equally rapid decrease of CCL2 and CXCL10 independent
of STAT1 expression.
It is unclear why STAT1 was elevated to such high levels
in some of the SLE patients and HD. One possibility is
from TLR activation as seen in the LPS stimulations. An-
other possibility is impairment in the expression of miR-
146a, which is known to target STAT1 [46]. In the paired
SLE-patient visits, miR-146a might be increased as a re-
sponse to STAT1 increases, but it is unable to downregulate
STAT1. One potential reason that miR-146a is unable todownregulate STAT1 is due to alternative splicing. STAT1
exists as a long form (STAT1a) and short form (STAT1b).
According to the miRNA target prediction site, TargetScan.
com, STAT1b has a shorter 3′ UTR compared to STAT1a
3′ UTR. The shorter 3′ UTR in STAT1b lacks miR-146a
binding sites, which would prevent miR-146a downregula-
tion of STAT1b. Several HD also displayed very high
STAT1 levels, however CCL2 and CXCL10, even though el-
evated compared to low-STAT1 HD, were significantly
lower than in SLE patients. A potential reason is that IFN-I
drives CCL2 and CXCL10 expression, and high STAT1
primes the immune system to amplify CCL2 and CXCL10
expression when IFN-I is present. Without IFN-I, the high
STAT1 levels may still prime the immune system but they
lack the ignition to drive the process forward.
Conclusions
The results of this study show that STAT1 mRNA expres-
sion in PBMCs from lupus patients and healthy controls is
segregated into high- or low-STAT1 groups. STAT1 may
be an important driver of lupus pathogenesis with STAT1
serving as an expression enhancer of CCL2 and CXCL10
in patients with high levels of STAT1.
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